Currently, out of the existing stock ratings of Christopher Neyor - 9 which are a Hold (52.94%), 1 which are a Sell (5.88%), 7 which are a Buy (41.18%)

Christopher Neyor

Work Performance Price Targets & Ratings Chart

Analyst Christopher Neyor works at JPMORGAN and is covering the Healthcare sector with 26 price targets and ratings displayed on 2 stocks.

Christopher Neyor's average stock forecast success ratio is 41.67% with an average time for price targets to be met of 91.5 days.

Most recent stock forecast was given on KALA, Kala Pharmaceuticals at 30-Mar-2022.

Wall Street Analyst Christopher Neyor

Analyst best performing recommendations are on PCRX (PACIRA BIOSCIENCES).
The best stock recommendation documented was for PCRX (PACIRA BIOSCIENCES) at 11/2/2018. The price target of $50 was fulfilled within 3 days with a profit of $0.32 (0.64%) receiving and performance score of 2.12.

Average potential price target upside

PCRX Pacira BioSciences KALA Kala Pharmaceuticals

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

52

$17.51 (50.77%)

60

1 months 18 days ago

9/17 (52.94%)

$16.87 (36.56%)

291

Buy

50

$15.51 (44.97%)

80

1 months 18 days ago

17/23 (73.91%)

$14.11 (30.71%)

490

Buy

63

$28.51 (82.66%)

68

1 months 18 days ago

8/18 (44.44%)

$19.4 (41.33%)

162

Hold

50

$15.51 (44.97%)

50

1 months 18 days ago

1/3 (33.33%)

$4.8 (12.67%)

26

Hold

52

$17.51 (50.77%)

60

8 months 15 days ago

25/28 (89.29%)

$1.94 (3.07%)

65

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Christopher Neyor?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart